

Clinical trial results:

A Phase 2, Interventional, Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects with Immune Thrombocytopenia Purpura Receiving Romiplostim Summary

Results information	
Trial information	
Trial identification	
Additional study identifiers	
Sponsors	
Paediatric regulatory details	

Results analysis stage	
General information about the tri	al
General information about the tri	aı
Population of trial subjects	
Subjects enrolled per country	
Subjects enrolled per country	
Subjects on rolled new and arrange	
Subjects enrolled per age group	

Subject disposition		
Recruitment		
Pre-assignment		
Period 1		
Period 1	1	
Arms		
Arm title		
	•	
Number of subjects in period 1		



Reporting groups Reporting group values


Baseline characteristics


		1		1
End point values				
Statistical analyses				
Secondary: Percentage of su treatment period	ıbjects with sple	nectomy durin	g the 12-moi	nth
<u> </u>				
				_
		1	<u> </u>	1
End point values				
a				
Statistical analyses				
Secondary: Number of subje	cts who develop	ed antibodies	to romiplosti	m
-			-	
	l			
	1			

End point values			
Statistical analyses			
Secondary: Number of subjects	with adverse	events	
<u> </u>			
	_!		
End point values	1		
ena point vaiues	+		
End point values	+		
end point values	+		
End point values			
End noint values			


a		
Statistical analyses		

Adverse events Adverse events information Dictionary used Reporting groups Serious adverse events





Non-serious adverse events					



More information

Substantial protocol amendments (globally)

Date	Amendment	

Interruptions (globally)

Limitations and caveats